QuidelOrtho Corp. Stock Plummets to New 52-Week Low of $19.24

QuidelOrtho Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 19.24 as of March 9, 2026. This marks a significant decline, with the stock's performance over the past year reflecting a decrease of 51.7%, starkly contrasting with the S&P 500's gain of 17.78% during the same period. The company's financial metrics indicate a challenging landscape, characterized by a debt-equity ratio of 1.31 and a return on equity of -7.95%. QuidelOrtho has not reported a profit in recent quarters, with a notable decline in profits of 272.8% over the past year. The stock's price-to-book ratio stands at 0.80, suggesting it is trading below its book value. Despite the current market conditions, QuidelOrtho's performance has consistently underperformed against the S&P 500 over the last three years, highlighting ongoing difficulties in achieving positive financial results. The company has reported negative results for 12 consecutive quarters, further emphasizing the challenges it faces in the competitive biotechnology landscape.